KY Biotechnology & Medical Research

NovaBridge Biosciences (NBP)

Track

Track

NovaBridge Biosciences experienced six insider trading transactions over the past ninety days, all involving sales totaling approximately 177,493 USD. Key executives, including the Chief Medical Officer and Business Development lead, offloaded shares amid a 32.6% decline in stock value. These divestments occurred following a September results financiers report that showed a 50% earnings beat.
Ticker: NBP Exchange: NMS
Preparing chart...
Download chart Copy chart image Copy link Share to X Share


• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Buy signal Sell signal Earnings
Upgrade for signal details

Upgrade to see score, net flow, insiders and context.

Upgrade to see full signal details →

Insider trades have triggered activity signals for NovaBridge Biosciences. Upgrade to see score, net flow, insiders and the full signal context.

Open in Activity Signals screener →
Top insiders
Trades
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
Dennis Phillip Andrew Chief Medical Officer Officer
Transaction date
Sale
Price
212.55
Quantity 54,382 -48.4%
Value US$3,230,707
Dennis Phillip Andrew Chief Medical Officer Officer
Transaction date
Proposed sale
Price
306.47
Quantity 12,679
Value US$853,715
3.1
Cao Sean Wuxiong Chief Bus. Development Officer Officer
Transaction date
Sale
Price
460.05
Quantity 58,878 +31.5%
Value US$1,030,437
3.1
Cao Sean Wuxiong Officer; CHIEF BUSINESS DEVELOPMENT OFFICER Officer
Transaction date
Proposed sale
Price
1.69
Quantity 46,947
Value US$79,378
Xu Cong Claire EVP, Clinical Development Officer
Transaction date
Sale
Price
0.79
Quantity 3,282 -1.1%
Value US$2,593
Xu Cong Claire SVP, Clinical Development Officer
Transaction date
Sale
Price
0.89
Quantity 4,485 -1.5%
Value US$3,992
Dennis Phillip Andrew Chief Medical Officer Officer
Transaction date
Sale
Price
0.66
Quantity 8,494 -5.1%
Value US$5,606
Dennis Phillip Andrew Chief Medical Officer Officer
Transaction date
Sale
Price
0.66
Quantity 8,494 -5.1%
Value US$5,606
Xu Cong Claire SVP, Clinical Development Officer
Transaction date
Sale
Price
3.94
Quantity 3,494 -1.2%
Value US$13,766
3.1
Cao Sean Wuxiong See Remarks Executive Director
Transaction date
Sale
Price
1.99
Quantity 21,399 -37.9%
Value US$42,584
3.1
Cao Sean Wuxiong See Remarks Executive Director
Transaction date
Sale
Price
1.99
Quantity 21,399 -37.9%
Value US$42,584
3.1
Cao Sean Wuxiong Officer; CHIEF BUSINESS DEVELOPMENT OFFICER Officer
Transaction date
Proposed sale
Price
1.99
Quantity 9,304
Value US$18,534
0.6
Hagler Mark Arnold See Remarks Officer
Transaction date
Purchase
Price
2.51
Quantity 230,000 +inf%
Value US$577,300
Dennis Phillip Andrew Chief Medical Officer Officer
Transaction date
Proposed sale
Price
2.79
Quantity 3,638
Value US$10,153
Skelton Joseph W. Officer; FORMER CFO Officer
Transaction date
Proposed sale
Price
4.33
Quantity 120,000
Value US$519,600
Dennis Phillip Andrew CHIEF MEDICAL OFFICER Officer
Transaction date
Proposed sale
Price
4.23
Quantity 3,431
Value US$14,501
KANNAN RAJ Officer; CEO Officer
Transaction date
Proposed sale
Price
1.39
Quantity 50,000
Value US$69,500
KANNAN RAJ Officer; CEO Officer
Transaction date
Proposed sale
Price
1.63
Quantity 300,000
Value US$489,000
Feng Gigi Qi Officer; CHIEF COMMUNICATIONS OFFICER Officer
Transaction date
Proposed sale
Price
1.80
Quantity 150
Value US$270
Tang Weimin Officer; CHIEF BUSINESS OFFICER Officer
Transaction date
Proposed sale
Price
2.00
Quantity 20,000
Value US$40,000
Zhu Andrew Officer; PRESIDENT AND ACTING CEO Officer
Transaction date
Proposed sale
Price
2.12
Quantity 30,000
Value US$63,600
Li Richard Cheng Officer; CHIEF LEGAL OFFICER Officer
Transaction date
Proposed sale
Price
1.83
Quantity 85,700
Value US$156,831
Feng Gigi Qi Officer; CHIEF COMMUNICATION OFFICER Officer
Transaction date
Proposed sale
Price
1.55
Quantity 20,000
Value US$31,000
Everest Medicines Ltd 10% Stockholder Large shareholder
Transaction date
Proposed sale
Price
0.73
Quantity 6,078,555
Value US$4,466,416
Tang Weimin Officer; CHIEF BUSINESS OFFICER Officer
Transaction date
Proposed sale
Price
1.27
Quantity 3,000
Value US$3,810
Hayslip John Officer; CHIEF MEDICAL OFFICER Officer
Transaction date
Proposed sale
Price
2.76
Quantity 29,000
Value US$80,040
Zhu Andrew Officer; PRESIDENT Officer
Transaction date
Proposed sale
Price
2.94
Quantity 97,300
Value US$286,062
Tang Weimin Officer; CHIEF BUSINESS OFFICER Officer
Transaction date
Proposed sale
Price
2.94
Quantity 23,800
Value US$69,972
Li Richard Cheng Officer; CHIEF LEGAL OFFICER Officer
Transaction date
Proposed sale
Price
2.94
Quantity 17,800
Value US$52,332
Yeh Richard Officer; COO interim CFO Officer
Transaction date
Proposed sale
Price
3.08
Quantity 33,000
Value US$101,640
Notification date Transaction date B/S Transaction type Insider and/or position Nb. shares
Price
Value 		Number of shares Price Value Details
2026-09-21 2026-09-18 S Sale
Dennis Phillip Andrew

Chief Medical Officer

Officer
54,382 -48.4%
212.55
US$3,230,707 		54,382 -48.4% 212.55 US$3,230,707
2026-09-18 2026-09-18 PrS Proposed sale
Dennis Phillip Andrew

Chief Medical Officer

Officer
12,679
306.47
US$853,715 		12,679 306.47 US$853,715
2026-09-11 2026-09-09 S Sale
3.1
Cao Sean Wuxiong

Chief Bus. Development Officer

Officer
58,878 +31.5%
460.05
US$1,030,437 		58,878 +31.5% 460.05 US$1,030,437
2026-09-09 2026-09-09 PrS Proposed sale
3.1
Cao Sean Wuxiong

Officer; CHIEF BUSINESS DEVELOPMENT OFFICER

Officer
46,947
1.69
US$79,378 		46,947 1.69 US$79,378
2026-09-01 2026-08-31 S Sale
Xu Cong Claire

EVP, Clinical Development

Officer
3,282 -1.1%
0.79
US$2,593 		3,282 -1.1% 0.79 US$2,593
2026-07-07 2026-07-06 S Sale
Xu Cong Claire

SVP, Clinical Development

Officer
4,485 -1.5%
0.89
US$3,992 		4,485 -1.5% 0.89 US$3,992
2026-06-22 2026-06-18 S Sale
Dennis Phillip Andrew

Chief Medical Officer

Officer
8,494 -5.1%
0.66
US$5,606 		8,494 -5.1% 0.66 US$5,606
2026-06-22 2026-06-18 S Sale
Dennis Phillip Andrew

Chief Medical Officer

Officer
8,494 -5.1%
0.66
US$5,606 		8,494 -5.1% 0.66 US$5,606
2026-06-02 2026-06-01 S Sale
Xu Cong Claire

SVP, Clinical Development

Officer
3,494 -1.2%
3.94
US$13,766 		3,494 -1.2% 3.94 US$13,766
2026-05-18 2026-05-14 S Sale
3.1
Cao Sean Wuxiong

See Remarks

Executive Director
21,399 -37.9%
1.99
US$42,584 		21,399 -37.9% 1.99 US$42,584
2026-05-18 2026-05-14 S Sale
3.1
Cao Sean Wuxiong

See Remarks

Executive Director
21,399 -37.9%
1.99
US$42,584 		21,399 -37.9% 1.99 US$42,584
2026-05-14 2026-05-14 PrS Proposed sale
3.1
Cao Sean Wuxiong

Officer; CHIEF BUSINESS DEVELOPMENT OFFICER

Officer
9,304
1.99
US$18,534 		9,304 1.99 US$18,534
2026-04-28 2026-04-24 B Purchase
0.6
Hagler Mark Arnold

See Remarks

Officer
230,000 +inf%
2.51
US$577,300 		230,000 +inf% 2.51 US$577,300
2026-03-18 2026-03-18 PrS Proposed sale
Dennis Phillip Andrew

Chief Medical Officer

Officer
3,638
2.79
US$10,153 		3,638 2.79 US$10,153
2026-01-02 2026-01-02 PrS Proposed sale
Skelton Joseph W.

Officer; FORMER CFO

Officer
120,000
4.33
US$519,600 		120,000 4.33 US$519,600
2025-12-18 2025-12-18 PrS Proposed sale
Dennis Phillip Andrew

CHIEF MEDICAL OFFICER

Officer
3,431
4.23
US$14,501 		3,431 4.23 US$14,501
2024-07-26 2024-07-26 PrS Proposed sale
KANNAN RAJ

Officer; CEO

Officer
50,000
1.39
US$69,500 		50,000 1.39 US$69,500
2024-07-17 2024-07-17 PrS Proposed sale
KANNAN RAJ

Officer; CEO

Officer
300,000
1.63
US$489,000 		300,000 1.63 US$489,000
2024-03-15 2024-03-15 PrS Proposed sale
Feng Gigi Qi

Officer; CHIEF COMMUNICATIONS OFFICER

Officer
150
1.80
US$270 		150 1.80 US$270
2024-02-08 2024-02-08 PrS Proposed sale
Tang Weimin

Officer; CHIEF BUSINESS OFFICER

Officer
20,000
2.00
US$40,000 		20,000 2.00 US$40,000
2024-01-05 2024-01-05 PrS Proposed sale
Zhu Andrew

Officer; PRESIDENT AND ACTING CEO

Officer
30,000
2.12
US$63,600 		30,000 2.12 US$63,600
2023-12-29 2023-12-29 PrS Proposed sale
Li Richard Cheng

Officer; CHIEF LEGAL OFFICER

Officer
85,700
1.83
US$156,831 		85,700 1.83 US$156,831
2023-12-26 2023-12-26 PrS Proposed sale
Feng Gigi Qi

Officer; CHIEF COMMUNICATION OFFICER

Officer
20,000
1.55
US$31,000 		20,000 1.55 US$31,000
2023-10-10 2023-10-24 PrS Proposed sale
Everest Medicines Ltd

10% Stockholder

Large shareholder
6,078,555
0.73
US$4,466,416 		6,078,555 0.73 US$4,466,416
2023-09-29 2023-09-29 PrS Proposed sale
Tang Weimin

Officer; CHIEF BUSINESS OFFICER

Officer
3,000
1.27
US$3,810 		3,000 1.27 US$3,810
2023-07-11 2023-07-11 PrS Proposed sale
Hayslip John

Officer; CHIEF MEDICAL OFFICER

Officer
29,000
2.76
US$80,040 		29,000 2.76 US$80,040
2023-07-05 2023-07-05 PrS Proposed sale
Zhu Andrew

Officer; PRESIDENT

Officer
97,300
2.94
US$286,062 		97,300 2.94 US$286,062
2023-07-05 2023-07-05 PrS Proposed sale
Tang Weimin

Officer; CHIEF BUSINESS OFFICER

Officer
23,800
2.94
US$69,972 		23,800 2.94 US$69,972
2023-07-05 2023-07-05 PrS Proposed sale
Li Richard Cheng

Officer; CHIEF LEGAL OFFICER

Officer
17,800
2.94
US$52,332 		17,800 2.94 US$52,332
2023-05-01 2023-05-01 PrS Proposed sale
Yeh Richard

Officer; COO interim CFO

Officer
33,000
3.08
US$101,640 		33,000 3.08 US$101,640
Explore more

More insider trading research around NovaBridge Biosciences

More insider trades in KY
Similar Healthcare companies with insider activity
More Pharmaceuticals & Medical Research companies with insider activity
More Biotechnology & Medical Research companies with insider activity